Cargando…

YKL-40 is correlated with FEV(1) and the asthma control test (ACT) in asthmatic patients: influence of treatment

BACKGROUND: YKL-40 is also called chitinase-3-like-1 (CHI3L1) protein and may be a marker for asthma. The aims of the present study were to investigate whether serum YKL-40 levels are stable or decreased in patients with asthma after appropriate treatment and to evaluate the correlation of YKL-40 le...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Tianwen, Chen, Min, Deng, Zaichun, Lǚ, Yingying, Wu, Dong, Li, Dongming, Wu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417200/
https://www.ncbi.nlm.nih.gov/pubmed/25578181
http://dx.doi.org/10.1186/1471-2466-15-1
_version_ 1782369328740433920
author Lai, Tianwen
Chen, Min
Deng, Zaichun
Lǚ, Yingying
Wu, Dong
Li, Dongming
Wu, Bin
author_facet Lai, Tianwen
Chen, Min
Deng, Zaichun
Lǚ, Yingying
Wu, Dong
Li, Dongming
Wu, Bin
author_sort Lai, Tianwen
collection PubMed
description BACKGROUND: YKL-40 is also called chitinase-3-like-1 (CHI3L1) protein and may be a marker for asthma. The aims of the present study were to investigate whether serum YKL-40 levels are stable or decreased in patients with asthma after appropriate treatment and to evaluate the correlation of YKL-40 levels with lung function and asthma control test (ACT) results. METHODS: A total of 103 asthmatic patients (mean age 33.1 ± 0.9 years) with diagnosed asthma were enrolled in our study. All patients underwent a detailed clinical examination and completed the ACT questionnaire, serum YKL-40 measurement, and spirometry before (visit 1) and 8 weeks after initiation of treatment (visit 2). RESULTS: At the follow-up, the median serum YKL-40 level was significantly decreased compared to the levels at visit 1 (75.2 [55.8-86.8] ng/ml versus 54.5 [46.4-58.4] ng/ml, p < 0.001). The serum YKL-40 level was negatively correlated with %FEV(1) (r = -0.37, p < 0.001) and ACT score (r = -0.26, p = 0.007) at visit 1. The change in serum YKL-40 levels between the visits was significantly correlated with changes in FEV(1) (r = -0.28, p = 0.006) and ACT score (r = -0.22, p = 0.037). Patients with elevated YKL-40 levels had significantly greater corticosteroid use than patients with lower levels. CONCLUSIONS: YKL-40 was reduced in the serum of asthmatic patients after appropriate treatment, and the levels correlated with improvements in %FEV(1) and ACT. High levels of serum YKL-40 may be refractory to current asthma treatments. TRIAL REGISTRATION: ChiCTR-OCC-13003316 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2466-15-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4417200
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44172002015-05-03 YKL-40 is correlated with FEV(1) and the asthma control test (ACT) in asthmatic patients: influence of treatment Lai, Tianwen Chen, Min Deng, Zaichun Lǚ, Yingying Wu, Dong Li, Dongming Wu, Bin BMC Pulm Med Research Article BACKGROUND: YKL-40 is also called chitinase-3-like-1 (CHI3L1) protein and may be a marker for asthma. The aims of the present study were to investigate whether serum YKL-40 levels are stable or decreased in patients with asthma after appropriate treatment and to evaluate the correlation of YKL-40 levels with lung function and asthma control test (ACT) results. METHODS: A total of 103 asthmatic patients (mean age 33.1 ± 0.9 years) with diagnosed asthma were enrolled in our study. All patients underwent a detailed clinical examination and completed the ACT questionnaire, serum YKL-40 measurement, and spirometry before (visit 1) and 8 weeks after initiation of treatment (visit 2). RESULTS: At the follow-up, the median serum YKL-40 level was significantly decreased compared to the levels at visit 1 (75.2 [55.8-86.8] ng/ml versus 54.5 [46.4-58.4] ng/ml, p < 0.001). The serum YKL-40 level was negatively correlated with %FEV(1) (r = -0.37, p < 0.001) and ACT score (r = -0.26, p = 0.007) at visit 1. The change in serum YKL-40 levels between the visits was significantly correlated with changes in FEV(1) (r = -0.28, p = 0.006) and ACT score (r = -0.22, p = 0.037). Patients with elevated YKL-40 levels had significantly greater corticosteroid use than patients with lower levels. CONCLUSIONS: YKL-40 was reduced in the serum of asthmatic patients after appropriate treatment, and the levels correlated with improvements in %FEV(1) and ACT. High levels of serum YKL-40 may be refractory to current asthma treatments. TRIAL REGISTRATION: ChiCTR-OCC-13003316 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2466-15-1) contains supplementary material, which is available to authorized users. BioMed Central 2015-01-12 /pmc/articles/PMC4417200/ /pubmed/25578181 http://dx.doi.org/10.1186/1471-2466-15-1 Text en © Lai et al.; licensee BioMed Central. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Lai, Tianwen
Chen, Min
Deng, Zaichun
Lǚ, Yingying
Wu, Dong
Li, Dongming
Wu, Bin
YKL-40 is correlated with FEV(1) and the asthma control test (ACT) in asthmatic patients: influence of treatment
title YKL-40 is correlated with FEV(1) and the asthma control test (ACT) in asthmatic patients: influence of treatment
title_full YKL-40 is correlated with FEV(1) and the asthma control test (ACT) in asthmatic patients: influence of treatment
title_fullStr YKL-40 is correlated with FEV(1) and the asthma control test (ACT) in asthmatic patients: influence of treatment
title_full_unstemmed YKL-40 is correlated with FEV(1) and the asthma control test (ACT) in asthmatic patients: influence of treatment
title_short YKL-40 is correlated with FEV(1) and the asthma control test (ACT) in asthmatic patients: influence of treatment
title_sort ykl-40 is correlated with fev(1) and the asthma control test (act) in asthmatic patients: influence of treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417200/
https://www.ncbi.nlm.nih.gov/pubmed/25578181
http://dx.doi.org/10.1186/1471-2466-15-1
work_keys_str_mv AT laitianwen ykl40iscorrelatedwithfev1andtheasthmacontroltestactinasthmaticpatientsinfluenceoftreatment
AT chenmin ykl40iscorrelatedwithfev1andtheasthmacontroltestactinasthmaticpatientsinfluenceoftreatment
AT dengzaichun ykl40iscorrelatedwithfev1andtheasthmacontroltestactinasthmaticpatientsinfluenceoftreatment
AT luyingying ykl40iscorrelatedwithfev1andtheasthmacontroltestactinasthmaticpatientsinfluenceoftreatment
AT wudong ykl40iscorrelatedwithfev1andtheasthmacontroltestactinasthmaticpatientsinfluenceoftreatment
AT lidongming ykl40iscorrelatedwithfev1andtheasthmacontroltestactinasthmaticpatientsinfluenceoftreatment
AT wubin ykl40iscorrelatedwithfev1andtheasthmacontroltestactinasthmaticpatientsinfluenceoftreatment